Max Planck Institute, Qiagen develop latent TB test; University of Exeter creates £20 million research center;

> Max Planck Institute for Infection Biology and Qiagen are developing a multiple biomarker test for people with latent tuberculosis that could identify their risk of developing the full-blown disease. Press release

> A new £20 million interdisciplinary research center at the University of Exeter will bring together researchers from biology, medicine, engineering mathematics and physics in translational research, including biomarker discovery. Press release

> Researchers have found the receptor for the breast cancer biomarker tumor differentiating factor (TDF). Press release

> Urine biomarkers could help in the emergency identification of acute kidney injury, thereby helping to speed up treatment. Press release

> C-reactive protein shows clinical use in kidney cancer, identifying patients at high risk of recurrence. Study

> A serum protein shows potential as a biomarker in liver cancer. Abstract

> Spinal fluid biomarkers link up with memory tests in mild cognitive impairment, a precursor of Alzheimer's disease. Abstract

Suggested Articles

Spinal Elements, maker of a wide range of implants and products for minimally invasive spine procedures, has filed a $100 million IPO.

United Airlines will begin providing COVID-19 screening tests for passengers, allowing those who test negative to skip local quarantine requirements.

Babson Diagnostics has closed its series A funding round with a total of $13.7 million and named a new CEO.